Genscript Biotech Corporation Net Asset Quality Index
Genscript Biotech Corporation net asset quality index. Genscript Biotech Corporation (G51) has a Net Asset Quality Index of 81.7% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €4.85 Billion minus total liabilities of €888.59 Million yields net assets of €3.96 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check G51 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Genscript Biotech Corporation (2016–2025)
Net asset quality index of Genscript Biotech Corporation from 2016 to 2025. This chart shows how Genscript Biotech Corporation's Net Asset Quality Index has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the index stands at 81.7%, representing net assets of €3.96 Billion against total assets of €4.85 Billion EUR. See Genscript Biotech Corporation book value and equity for net asset value and shareholders' equity analysis.
Genscript Biotech Corporation Net Asset Quality Index by Year (2016–2025)
Genscript Biotech Corporation net asset quality index by year from 2016 to 2025. The table below presents the year-by-year Net Asset Quality Index for Genscript Biotech Corporation from 2016 to 2025, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Genscript Biotech Corporation (G51) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.7% | €3.96 Billion | €4.85 Billion | €888.59 Million | ▼ -0.2 pp |
| 2024 | 81.9% | €4.32 Billion | €5.28 Billion | €954.91 Million | ▲ +21.6 pp |
| 2023 | 60.4% | €2.04 Billion | €3.39 Billion | €1.34 Billion | ▲ +6.8 pp |
| 2022 | 53.5% | €1.36 Billion | €2.55 Billion | €1.18 Billion | ▲ +4.6 pp |
| 2021 | 49.0% | €1.09 Billion | €2.23 Billion | €1.14 Billion | ▼ -7.4 pp |
| 2020 | 56.3% | €815.59 Million | €1.45 Billion | €631.82 Million | ▲ +14.5 pp |
| 2019 | 41.9% | €372.30 Million | €889.41 Million | €517.11 Million | ▼ -11.9 pp |
| 2018 | 53.8% | €493.30 Million | €916.98 Million | €423.68 Million | ▲ +8.5 pp |
| 2017 | 45.3% | €228.32 Million | €504.26 Million | €275.94 Million | ▼ -36.1 pp |
| 2016 | 81.4% | €184.02 Million | €226.03 Million | €42.01 Million | — |